Recent profiling of the AML cancer genome with next-generation sequencing has demonstrated that most AML mutations are recurrent, consisting primarily of chromosomal translocation events at specific loci and targeted mutations among a group of 23 genes, including epigenetic regulators such as DNMT3A, TET2, and RUNX1 [8]. This evidence concerns the gene DNMT3A and acute myeloid leukemia.